Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | APAF1 | O14727 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HK1 | P19367 | 1/20 | 0.32 |
| ▸ | GALK1 | P51570 | 1/20 | 0.32 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8905893 | 0.85 | IDO1 (0.33) | IDO1 | |
| SCHEMBL30168823 | 0.85 | IDO1 (0.33) | IDO1 | |
| SCHEMBL27840600 | 0.84 | IDO1 (0.32) | IDO1 | |
| SCHEMBL29941302 | 0.76 | MEN1 (0.39) | GSK3BALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL29352286 | 0.70 | MAPT (0.40) | IDO1GSK3BALDH1A1LMNAMAPT | |
| SCHEMBL1120300 | 0.70 | MAPT (0.40) | IDO1GSK3BALDH1A1LMNAMAPT | |
| Trifluoroacetic Acid SCHEMBL6241485 | 0.70 | MAPT (0.35) | IDO1GSK3BALDH1A1LMNAMAPT | |
| SCHEMBL3226013 | 0.66 | IDO1 (0.37) | IDO1GSK3BALDH1A1LMNAMAPT | |
| SCHEMBL28007761 | 0.65 | IDO1 (0.33) | IDO1ALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL6353728 | 0.64 | KDM4E (0.30) | ALDH1A1MAPTKDM4ETSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2354240-B1 | Polypeptides and biosynthetic pathways | CARGILL INC (US) | 2016-07-06 | — | — | EP | disclosed |
| US-9034610-B2 | Polypeptides and biosynthetic pathways for the production of monatin and its precursors | CARGILL, INCORPORATED (US) | 2015-05-19 | — | — | US | disclosed |
| US-20130273616-A1 | POLYPEPTIDES AND BIOSYNTHETIC PATHWAYS FOR THE PRODUCTION OF MONATIN AND ITS PRECURSORS | CARGILL INC (US) | 2013-10-17 | — | — | US | disclosed |
| US-20130203129-A1 | POLYPEPTIDES AND BIOSYNTHETIC PATHWAYS FOR THE PRODUCTION OF MONATIN AND ITS PRECURSORS | CARGILL, INCORPORATED (US) | 2013-08-08 | — | — | US | disclosed |
| US-8440434-B2 | Contacting a HEXAspC aminotransferase with tryptophan or 2-hydroxy 2-(indol-3-ylmethyl)-4-keto glutaric acid to facilitate a conversion of tryptophan to indole-3-pyruvate, a conversion of 2-hydroxy 2-(indol-3-ylmethyl)-4-keto glutaric acid to 2-Hydroxy-2-(indol-3-ylmethyl)-4-aminoglutaric acid (monatin) | CARGILL, INCORPORATED (US) | 2013-05-14 | — | — | US | disclosed |
| US-8435765-B2 | Polypeptides and biosynthetic pathways for the production of monatin and its precursors | CARGILL, INCORPORATED (US) | 2013-05-07 | — | — | US | disclosed |
| US-8372989-B2 | Polypeptides and biosynthetic pathways for the production of monatin and its precursors | CARGILL, INCORPORATED (US) | 2013-02-12 | — | — | US | disclosed |
| EP-2354240-A1 | Polypeptides and biosynthetic pathways | CARGILL, INCORPORATED (US) | 2011-08-10 | — | — | EP | disclosed |
| EP-1503985-B1 | POLYPEPTIDES AND BIOSYNTHETIC PATHWAYS | CARGILL INC (US) | 2010-12-15 | — | — | EP | disclosed |
| US-7572607-B2 | Polypeptides and biosynthetic pathways for the production of monatin and its precursors | CARGILL, INCORPORATED (US) | 2009-08-11 | — | — | US | disclosed |
| US-20050282260-A1 | Polypeptides and biosynthetic pathways for the production of monatin and its precursors | CARGILL, INCORPORATED | 2005-12-22 | — | — | US | disclosed |
| US-20050244937-A1 | Contacting a polypeptide with tryptophan or 2-hydroxy 2-(indol-3-ylmethyl)-4-keto glutaric acid to facilitate a conversion of tryptophan to indole-3-pyruvate, a conversion of 2-hydroxy 2-(indol-3-ylmethyl)-4-keto glutaric acid to 2-Hydroxy-2-(indol-3-ylmethyl)-4-aminoglutaric acid (monatin) | CARGILL, INC. | 2005-11-03 | — | — | US | disclosed |
| EP-1503985-A2 | POLYPEPTIDES AND BIOSYNTHETIC PATHWAYS | Cargill, Incorporated (US) | 2005-02-09 | — | — | EP | disclosed |
| US-20040063175-A1 | Polypeptides and biosynthetic pathways | CARGILL, INCORPORATED | 2004-04-01 | — | — | US | disclosed |
| WO-2003091396-A2 | POLYPEPTIDES AND BIOSYNTHETIC PATHWAYS | CARGILL, INCORPORATED (US) | 2003-11-06 | — | — | WO | disclosed |
| EP-0457318-B1 | Alpha-Oxopyrrolo[2,3-b]indole acetic acids, esters, amides and related analogs, a process for their preparation and their use as medicaments | HOECHST ROUSSEL PHARMA (US) | 1996-08-14 | — | — | EP | disclosed |
| EP-0457318-B1 | Alpha-Oxopyrrolo[2,3-b]indole acetic acids, esters, amides and related analogs, a process for their preparation and their use as medicaments | HOECHST ROUSSEL PHARMA (US) | 1996-08-14 | — | — | EP | disclosed |
| US-5264587-A | Method of preparing α-oxopyrrolo[2,3-b]indole acetic acids and derivatives | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1993-11-23 | — | — | US | disclosed |
| US-5173497-A | Treatment of memory impairment characterized by cholinergic deficit | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1992-12-22 | — | — | US | disclosed |
| EP-0457318-A1 | Alpha-Oxopyrrolo[2,3-b]indole acetic acids, esters, amides and related analogs, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1991-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050244937-A1 | Contacting a polypeptide with tryptophan or 2-hydroxy 2-(indol-3-ylmethyl)-4-keto glutaric acid to facilitate a conversion of tryptophan to indole-3-pyruvate, a conversion of 2-hydroxy 2-(indol-3-ylmethyl)-4-keto glutaric acid to 2-Hydroxy-2-(indol-3-ylmethyl)-4-aminoglutaric acid (monatin) | AADAT, KYAT3, MON2 | IDO1 18/4885GSK3B 751/4885ALDH1A1 2894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.